A revolution in clinical cancer genomics

Inivata: Liquid biopsies to clinical outcomes

Inivata, a global clinical cancer genomics company, is employing the precision of circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology.  Using a simple blood test, ctDNA analysis is a new tool for oncologists to detect cancer, stratify patients, and assess individual response to treatment.  This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored and treated.

Inivata's proprietary technology is based on pioneering research from the Rosenfeld Lab at Cancer Research (CRUK), Cambridge.  Inivata’s platform brings together Next-Generation Sequencing (NGS) technology, proprietary algorithms, and databases that correlate genomic profiles to actual clinical outcomes.

Highlights
Apr 15, 2016
News: Inivata to present results of analytical validation at the AACR Annual Meeting 2016 Read more
Jan 26, 2016
News: Inivata Completes £31.5 Million ($45M) Series A Fundraising Round Read more
Apr 14, 2016
Event: Inivata to present analytical validation at AACR, Tuesday April 19th Read more
Mar 21, 2016
Event: John Beeler to speak Monday 21st, March at Circulating Biomarkers World Congress 2016, Boston Read more
© Copyright Inivata Ltd 2016

Home

About us

  1. About us
  2. Management
  3. Board
  4. Investors

Technology

  1. Technology
  2. TAm-Seq

News and Events

  1. News and Events
  2. Upcoming Conferences
  3. Publications
  4. Conference presentations

Careers

Contact us

A revolution in clinical cancer genomics

Inivata: Liquid biopsies to clinical outcomes

Inivata, a global clinical cancer genomics company, is employing the precision of circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology.  Using a simple blood test, ctDNA analysis is a new tool for oncologists to detect cancer, stratify patients, and assess individual response to treatment.  This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored and treated.

Inivata's proprietary technology is based on pioneering research from the Rosenfeld Lab at Cancer Research (CRUK), Cambridge.  Inivata’s platform brings together Next-Generation Sequencing (NGS) technology, proprietary algorithms, and databases that correlate genomic profiles to actual clinical outcomes.

Highlights
Apr 15, 2016
News: Inivata to present results of analytical validation at the AACR Annual Meeting 2016 Read more
Jan 26, 2016
News: Inivata Completes £31.5 Million ($45M) Series A Fundraising Round Read more
Apr 14, 2016
Event: Inivata to present analytical validation at AACR, Tuesday April 19th Read more
Mar 21, 2016
Event: John Beeler to speak Monday 21st, March at Circulating Biomarkers World Congress 2016, Boston Read more
Cookie policy
© Copyright Inivata Ltd 2016